ALIMTA (Pemetrexed) Alone or in Combination With Cisplatin for Patients With Malignant Mesothelioma.
2 other identifiers
expanded_access
N/A
4 countries
6
Brief Summary
This study is to evaluate the effects (good and bad) of ALIMTA and Cisplatin or ALIMTA alone on you and your malignant pleural mesothelioma as well as make ALIMTA available to patients who qualify for treatment.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
6 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
July 2, 2002
CompletedFirst Posted
Study publicly available on registry
July 4, 2002
CompletedMarch 15, 2007
March 1, 2007
July 2, 2002
March 14, 2007
Conditions
Interventions
Eligibility Criteria
You may qualify if:
- Have a proven diagnosis of malignant mesothelioma in patients not candidates for curative surgery
- Prior chemotherapy for your disease is allowed
- Measurable lesion is not required
- Have a adequate performance status
- Sign an informed consent form
You may not qualify if:
- You are excluded from this trial if you have received any investigational agent within 4 week before enrolling in this study
- You are excluded from this trial if you have received radiation within the previous 2 weeks
- You are excluded from this trial if you are a candidates for curative surgery
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (6)
For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY(1-877-285-4559) or speak with your personal physician.
Basking Ridge, New Jersey, United States
For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician
Porto Alegre, Rio Grande do Sul, Brazil
For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician
São Paulo, Brazil
"For additional information regarding investigative sites for this trial, contact the Clinical Trials Support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician."
Cairo, Egypt
For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician
Cairo, Egypt
For additional information regarding investigative sites for this trial, contact the Clinical Trials support Center at 1-877-CTLILLY (1-877-285-4559) or speak with your personal physician
Jeddah, Saudi Arabia